On January 12, URAC submitted comments in response to the Centers for Medicare and Medicaid Services’ (CMS) proposed rule for Medicare Advantage for 2019. As part of the proposed rule, CMS requests feedback regarding the role that accreditation, namely accreditation of specialty pharmacies, plays in Part D. CMS noted anecdotal concerns that have been reported regarding the potential limiting nature of Part D contracts that require pharmacies to maintain Specialty Pharmacy Accreditation.
Specialty pharmacies can enhance patient care, serve more customers, and expand the provider network if they pursue accreditation with an across the board commitment and a clear understanding of goals, says Heather Bonome, URAC director of pharmacy.
“Think of it as a way to organize and demonstrate your commitment to quality,” she says in a new podcast, “Pharmacy Accreditation: A URAC Perspective”, hosted by Christopher W. Kennedy, MSM, chief operating officer, Heritage Biologics, Inc.
The U.S. specialty pharmacy industry is growing. Much of that growth can be attributed to healthcare provider-owned pharmacies. This infographic provides a snapshot of some key statistics on the specialty pharmacy industry trend in hospital systems.
URAC White Paper Highlights the Changing Role of Specialty Pharmacy and Its Impact on Patient Outcomes
WASHINGTON, DC – April 19, 2017 –Independent accreditor URAC today released a new Industry Insight Report for specialty pharmacy providers entitled “Competing in the Specialty Pharmacy Market: Key Competencies for Performance in Value-Based Healthcare.” The report examines why specialty pharmacies need to incorporate a sixth right -- the right result -- to the traditional “five rights” of medication administration, to be successful in the value-based healthcare model. The patient-centric care model, when employed by specialty pharmacies, means working with individual patients and their providers to achieve the drug’s intended therapeutic result and prevent a costly hospital stay.